STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 71 filers reported holding STEMLINE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $289,000 | +20.9% | 26,000 | 0.0% | 0.35% | +27.0% |
| Q2 2017 | $239,000 | +7.7% | 26,000 | 0.0% | 0.28% | +14.4% |
| Q1 2017 | $222,000 | -20.1% | 26,000 | 0.0% | 0.24% | -18.2% |
| Q4 2016 | $278,000 | +4.1% | 26,000 | 0.0% | 0.30% | +17.4% |
| Q3 2016 | $267,000 | +50.0% | 26,000 | -1.2% | 0.25% | +51.5% |
| Q2 2016 | $178,000 | +63.3% | 26,305 | +12.9% | 0.17% | +67.0% |
| Q1 2016 | $109,000 | -6.0% | 23,305 | +27.3% | 0.10% | +9.9% |
| Q4 2015 | $116,000 | -41.4% | 18,305 | +9.0% | 0.09% | -32.6% |
| Q2 2015 | $198,000 | +7.0% | 16,796 | +31.3% | 0.14% | -2.2% |
| Q1 2015 | $185,000 | -26.6% | 12,796 | -13.5% | 0.14% | +1.5% |
| Q4 2014 | $252,000 | -9.0% | 14,796 | -33.3% | 0.14% | -8.7% |
| Q3 2014 | $277,000 | +30.0% | 22,196 | +53.1% | 0.15% | +40.6% |
| Q2 2014 | $213,000 | -10.1% | 14,500 | +19.8% | 0.11% | -17.8% |
| Q4 2013 | $237,000 | – | 12,100 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 762,941 | $7,248,000 | 7.29% |
| NEXTHERA CAPITAL LP | 711,558 | $6,760,000 | 2.79% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 585,930 | $4,366,000 | 2.71% |
| Consonance Capital Management LP | 1,155,793 | $10,980,000 | 0.81% |
| Pier Capital, LLC | 423,667 | $4,025,000 | 0.80% |
| KNOTT DAVID M | 155,795 | $1,480,000 | 0.70% |
| Eventide Asset Management | 1,086,400 | $10,321,000 | 0.46% |
| Empire Life Investments Inc. | 373,863 | $3,552,000 | 0.32% |
| Telemetry Investments, L.L.C. | 41,588 | $395,000 | 0.25% |
| Polar Capital LLP | 2,302,666 | $21,875,000 | 0.23% |